Volume 11, Number 9—September 2005
Dispatch
Multidrug-resistant Tuberculosis Detection, Latvia
Girts Skenders*, Alicia M. Fry†, Inga Prokopovica*, Silvija Greckoseja*, Lonija Broka*, Beverly Metchock†, Timothy H. Holtz†, Charles D. Wells†
, and Vaira Leimane*
, and Vaira Leimane*
Table 2
Drug-susceptibility profiles for patients at high risk for MDR-TB with acid-fast bacilli–positive respiratory specimens*†
| Drug resistance | No. (%) |
|---|---|
| None | 35 (40.0) |
| Any resistance | 52 (60.0) |
| Rifampin (total) | 34 (38.6) |
| Mono-rifampin | 1 (1.1) |
| MDR (total) | 33 (37.5) |
| R, H | 2 (2.3) |
| R, H, S | 17 (19.3) |
| R, H, S, E | 14 (15.9) |
| Isoniazid (total) | 52 (59) |
| Mono-isoniazid | 5 (5.7) |
| H, S | 14 (15.9) |
*N = 88; includes 86 Mycobacterium tuberculosis isolates from BACTEC plus 2 isolates that grew on Löwenstein-Jensen media.
†R, rifampin; H, isoniazid; S, streptomycin; E, ethambutol; MDR-TB, multidrug-resistant tuberculosis.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.